What Edwards Lifesciences's FY2025 10-K says: 11 signals
Edwards Lifesciences filed its latest 10-K with the SEC on Feb 25, 2026. It discusses bookings decline, capacity constraint and capex increase.
Public (EW)Medical Equipment Manufacturing10,000+ employeesedwards.comLinkedIn
- Filed
- Feb 25, 2026
- Period
- FY2025
- Fiscal year end
- 12/31
- Filings
- 1
10-K · latest 9
What Edwards Lifesciences's 10-K filings say
- SEC EDGAR
10-K · FY2025
Filed · Fiscal year ends 12/31 · 11 signals
Sales volumes constrained by hospital staffing shortages and facility competition.
Edwards is experiencing lower than forecasted sales because its hospital customers lack the necessary staff and catheterization laboratory capacity to perform procedures, creating a significant bottleneck to revenue growth.
Company is utilizing AI and flags failure to keep pace with emerging tech as a key business risk
Edwards is actively using AI in its operations but acknowledges significant risks related to rapid technological advancement, cybersecurity, data privacy, and intellectual property.
AIartificial intelligence
Highlights vulnerability to cybersecurity attacks, including ransomware and phishing.
The company is concerned about its IT infrastructure's vulnerability to various cyber threats and potential disruptions from attacks on its third-party cloud service providers, creating a need for enhanced security solutions.
cloud
Investing 18% of total 2025 sales into R&D for structural heart programs.
The company is dedicating a significant portion of its revenue, approximately 18% of sales, to R&D, with a primary focus on investments in transcatheter structural heart programs for mitral, aortic, and tricuspid therapies.
18%
of 2025 sales invested in R&D
Facing risks and potential costs from failure to effectively utilize AI and evolving regulations.
The company acknowledges risk if it fails to utilize AI for innovation faster than competitors and notes that compliance with new or changing AI laws may impose significant costs, creating a need for expertise in AI strategy and governance.
AI
R&D spending increased to 18% of sales in 2025, focused on new transcatheter therapies
Edwards increased R&D spending by 2% year-over-year, representing a significant budget of approximately 18% of 2025 sales.
18%
of 2025 sales allocated to Research and Development
Relies on single-source suppliers for critical components, creating supply chain vulnerability.
Edwards purchases certain supplies and services from single sources for quality and regulatory reasons, making it difficult to establish replacements and creating a material risk of supply interruptions, delays, and cost increases.
Launched KONECT RESILIA surgical product in Europe in 2025, expanding international presence
The company is expanding its surgical product portfolio internationally with the 2025 European launch of the KONECT RESILIA aortic valved conduit.
International sales account for 42% of net sales, with focus on Europe and Japan
In 2025, 42% of net sales were derived from outside the United States, with Europe comprising 60% of that international revenue.
42%
of net sales derived outside of the United States in 2025
Showing 9 of 11 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Edwards Lifesciences with the Signal API
One POST /v1/companies/enrich call with edwards.com returns Edwards Lifesciences 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"edwards.com","signal_types":["sec-10k"],"limit":20}'Same industry
10-K at related companies
Questions about Edwards Lifesciences 10-K
When did Edwards Lifesciences file its latest 10-K?
What does Edwards Lifesciences's latest 10-K say about bookings decline?
Where can I find Edwards Lifesciences's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .